Amyotroph Lateral Scler Frontotemporal Degener
-
Publication Venue For
- The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure.. 1-9. 2023
- ALSUntangled #65: glucocorticoid corticosteroids.. 24:351-357. 2023
- ALSUntangled #63: ketogenic diets.. 24:159-163. 2023
- Study of "ALS reversals": LifeTime environmental exposures (StARLiTE).. 24:54-62. 2023
- ALSUntangled # 69: astaxanthin.. 1-5. 2023
- ALSUntangled #68: ozone therapy.. 1-5. 2022
- ALSUntangled #64: butyrates.. 23:638-643. 2022
- ALSUntangled #67: rituximab.. 1-4. 2022
- ALSUntangled #62: vitamin C.. 23:476-479. 2022
- ALSUntangled #66: antimycobacterial antibiotics.. 1-5. 2022
- ALSUntangled #60: light therapy.. 23:315-319. 2022
- ALSUntangled #61: melatonin.. 23:157-160. 2022
- ALSUntangled 59: Tamoxifen.. 22:595-598. 2021
- ALSUntangled 57: Vinpocetine.. 22:316-319. 2021
- Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study.. 22:147-150. 2021
- Total serum immunoglobulin A in ALS.. 22:61-65. 2021
- ALSUntangled 56: "ten red flags"-things to be wary of in alternative or off-label products.. 21:642-647. 2020
- Understanding the needs of people with ALS: a national survey of patients and caregivers.. 21:355-363. 2020
- ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors.. 21:216-221. 2020
- Plasma creatinine and oxidative stress biomarkers in amyotrophic lateral sclerosis.. 21:263-272. 2020
- ALSUntangled 48: Perampanel (Fycompa).. 20:453-456. 2019
- ALSUntangled No. 47: RT001.. 20:294-297. 2019
- Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial.. 20:285-293. 2019
- ALSUntangled 46: penicillin G/hydrocortisone.. 20:126-131. 2019
- "ALS reversals": demographics, disease characteristics, treatments, and co-morbidities.. 19:495-499. 2018
- ALSUntangled 44: curcumin.. 19:623-629. 2018
- ALSUntangled 43: copper.. 19:472-476. 2018
- ALSUntangled 42: Elysium health's "basis".. 19:317-319. 2018
- A spatial analysis of amyotrophic lateral sclerosis (ALS) cases in the United States and their proximity to multidisciplinary ALS clinics, 2013.. 19:126-133. 2018
- ALSUntangled 41: "Eric Is Winning".. 19:157-160. 2018
- ALSUntangled No. 37: Inosine.. 18:309-312. 2017
- ALSUntangled 38: L-serine.. 18:148-151. 2017
- ALSUntangled No. 36: Accilion.. 18:142-147. 2017
- ALSUntangled No. 34: GM604.. 17:617-621. 2016
- ALSUntangled No. 35: Hyperbaric Oxygen Therapy.. 17:622-624. 2016
- ALSUntangled: introducing The Table of Evidence.. 16:142-145. 2015
- ALSUntangled No. 29: MitoQ.. 16:427-429. 2015
- ALSUntangled No. 26: lunasin.. 15:622-626. 2014
- ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.. 15:192-203. 2014
- ALS Untangled No. 20: the Deanna protocol.. 14:319-323. 2013
- Infrastructure resources for clinical research in amyotrophic lateral sclerosis.. 14 Suppl 1:53-61. 2013
- Peer recommendations on how to improve clinical research, and Conference wrap-up.. 14 Suppl 1:67-73. 2013